Aspire Rejuvenation sees surge in menopause hormone therapy questions after ACOG, FDA shifts

Aspire Rejuvenation says more women in Pennsylvania and Florida are asking about menopause hormone therapy after new guidance from the American College of Obstetricians and Gynecologists and a federal label change from the FDA. The shifts are changing how patients view a treatment many were previously told to avoid.

Why it matters: - New guidance from ACOG and a federal label update are pushing menopause hormone therapy back into mainstream discussion. - The changes could affect how women with hot flashes, night sweats and other menopause symptoms talk with clinicians about treatment. - Aspire Rejuvenation says the policy shift is showing up in patient demand, especially among women who were previously hesitant about hormone therapy.

What happened: - Aspire Rejuvenation said it has seen more women ask about menopause hormone therapy after ACOG expanded its support for the treatment and the FDA began removing broad black box warnings. - ACOG published a new clinical practice guideline on October 15, 2026, replacing its 2014 guidance. - The guideline strongly recommends systemic hormone therapy for hot flashes and night sweats in patients without contraindications. - ACOG says the therapy is ideally started before age 60 or within 10 years of menopause. - The FDA label change was announced on November 10, 2025, by the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary. - Boxed language on cardiovascular disease, breast cancer and probable dementia is coming off hormone therapy labels. - The endometrial cancer warning remains on estrogen-only products.

The details: - Aspire Rejuvenation was founded by Tomo Marjanovic and has offered individualized hormone care for women for years. - Dr. Joseph Clark, Aspire Rejuvenation's chief medical officer, said the clinic starts women's hormone care with comprehensive laboratory testing and a review of medical history before treatment is considered. - Dr. Clark diagnoses, prescribes and oversees treatment with Aspire's team of licensed nurse practitioners. - Aspire offers women's hormone care at its Pennsylvania clinics in Pittsburgh and Ebensburg. - Dr. Clark said women make up a larger share of patients in Pennsylvania than in any other Aspire market. - Aspire also serves patients in Orlando and Dallas. - Dr. Clark said menopause symptoms such as exhaustion, brain fog, poor sleep, lost desire and feeling disconnected from oneself should prompt a meaningful conversation about care. - Mirit Moon, founder of Moon Media Affairs, said she changed her view on hormone health after reading Tomo Marjanovic's book, Operation Optimal. - Moon said Dr. Clark is now part of her care team.

Between the lines: - The new ACOG guidance and FDA label changes signal a broader shift away from the long-standing caution that kept many women from asking about hormone therapy. - Aspire is positioning its model around individualized testing and follow-up, which may appeal to patients who want a more personalized approach than they previously received. - The company is using the policy changes as proof that the conversation around menopause care is changing, not just the treatment options.

What's next: - Aspire expects continued patient interest as more women learn that menopause hormone therapy is being viewed differently by major medical and federal authorities. - The clinic says it will keep offering hormone care through its physical locations and telemedicine. - Aspire also says domestic and international expansion is continuing. - Moon Media Affairs will continue representing Aspire Rejuvenation.